a r t i c l e s
To understand EMI1-mediated inhibition of APC/C, we performed a hybrid structural analysis. NMR studies indicated that other than the 45-residue ZBR, the 143-residue C-terminal EMI1 inhibitory region lacks fixed tertiary structure. Electron microscopy (EM) studies revealed that EMI1 interacts with, approaches and/or alters the conformations of numerous subunits of the ~1.5 MDa APC/C CDH1 molecular machine. The functional importance of intrinsic structural disorder is explained by the D-box, linker, ZBR and tail synergistically blocking both Ub ligation to a substrate and Ub-chain elongation by APC/C.
RESULTS

Structural dissection of EMI1's APC/C inhibitory domain
To guide structural studies, we analyzed the human EMI1 protein sequence with the program PONDR (http://www.pondr.com/index) to identify folded domains 25 . The majority of EMI1 is predicted to be intrinsically disordered, with the exception of a short N-terminal region, the F-box and the ZBR (Fig. 1a) . In the APC/C-inhibitory Cterminal domain, regions predicted to be unstructured include the D-box, linker region and tail. To test this hypothesis, we characterized structural properties for the EMI1 C-terminal domain (hereafter referred to as EMI1 DLZT for D-box, linker, ZBR, tail) by NMR. Backbone resonance assignments revealed that the chemical shifts were consistently dispersed for the ZBR residues in the EMI1 DLZT , EMI1 ZT and EMI1 Z constructs, indicating that the ZBR is an autonomously folded domain (Fig. 1b) . Notably, the remaining resonances in EMI1 DLZT displayed poor dispersion, low or negative { 1 H}- 15 N heteronuclear NOE (HetNOE) values and relatively low differences in Cα chemical shifts compared with values predicted for a random coil (Fig. 1c) . 
a r t i c l e s
Previous studies showed that mutation of ZBR cysteines or treatment with a metal chelator decreased EMI1's competition with substrate binding or inhibition of substrate ubiquitination by APC/C 19, 22 . We found that the addition of a metal chelator, EDTA, to 15 N-labeled EMI1 ZT eliminated the 15 N-1 H chemical shift dispersion that is characteristic of the folded structure, which was re-established by ZnSO 4 addition (Fig. 1d) . To resolve the ambiguity of one potential zinc-coordinating residue 19 , we ascertained that mutation of Cys409, but not Cys411, eliminated the hallmarks of folding in onedimensional proton NMR spectra (Fig. 1e) .
To further characterize the biophysical properties of EMI1 DLZT , we measured the hydrodynamic radius (R h ) to be 3.1 nm and 2.9 nm by dynamic light scattering (DLS) and analytical ultracentrifugation, respectively (Fig. 1f,g ). A globular protein would have to be ~46 kDa, rather than the 16.0 kDa of EMI1 DLZT , to yield an R h value of 3.1 nm by DLS. The best-fit, weight-average anhydrous frictional ratio (f/f 0 ) w values of 1.73 and 1.85 obtained from two analytical ultracentrifugation experiments indicate that EMI1 DLZT is elongated in solution (Supplementary Fig. 1) . Overall, the data suggest that EMI1 DLZT is substantially intrinsically unfolded, with predominantly disordered D-box, linker and tail regions separated by a folded ZBR.
EM reveals multisite EMI1 binding to APC/C CDH1
Previous EM studies revealed a structurally dynamic triangular APC/C architecture organized from three superdomains: (i) an 'arc lamp' comprising TPR subunits APC7, APC3, APC6 and APC8 and associated small subunits APC16, APC13 and CDC26; (ii) a 'platform' comprising APC1, APC4, APC5 and APC15; and (iii) a catalytic core, located between the arc lamp and platform, containing the APC2-APC11 cullin-RING complex and the substrate co-receptor, APC10 (ref. 6, 10) . These superdomains surround a large central cavity containing the substrate-binding site and proposed catalytic site 26 . Different conformers were observed for apo-APC/C, which vary in relative positions for the arc lamp and platform, reflecting the dynamic nature of the complex 10 . CDH1 binds APC3 in the arc lamp, with its substrate-binding WD40 domain projecting toward the catalytic core 27 .
To understand the structural basis for inhibition, we performed a series of single-particle reconstructions by negative-stain EM on complexes between APC/C purified from HeLa cells reconstituted with CDH1 and various versions of EMI1. Versions of EMI1 containing an F-box were complexed with SKP1. In comparison to human APC/C CDH1 (ref. 6), the APC/C CDH1 -EMI1-SKP1 complex displays additional prominent density, which we attribute to EMI1-SKP1 ( Fig. 2a and Supplementary Fig. 2a,b) . EMI1-SKP1 occupies and thus occludes access to the entire central cavity of APC/C. One edge of EMI1-SKP1 approaches the base of the arc lamp and the CDH1 WD40 domain. The other side is contiguous and integrated with the platform.
EM analysis further reveals that despite its small size, the inhibitory domain, EMI1 DLZT Fig. 2b and Supplementary Fig. 2c ). For the complexes with both EMI1-SKP1 and EMI1 DLZT , there are differences in the vicinity of the D-box co-receptors CDH1 and APC10 and additional density linking this region and the catalytic core and platform regions. Substantial additional density is also observed emanating from the platform. Notably, relative to prior apo-APC/C and APC/C CDH1 structures, in both EMI1-inhibited complexes the catalytic core forms a prominent contact with platform regions assigned to APC1 and APC4, which are repositioned. The density assigned to APC1 and APC4 has lost contact with APC5, is no longer in the position previously observed for apo-APC/C 26, 27 and is instead bent toward the catalytic core.
A difference map comparing the full APC/C CDH1 -EMI1-SKP1 complex with APC/C CDH1 -EMI1 DLZT reveals additional exposed density more distal from the APC/C central cavity and catalytic core, which we attribute to the N-terminal domain and SKP1-bound F-box ( Supplementary Fig. 2d ). This agrees with the location of extra density for a complex harboring a maltose-binding protein fused at the N terminus of SKP1 ( Supplementary Fig. 2e ).
Tight-binding inhibition of substrate ubiquitination
APC/C CDH1 utilizes a two-step mechanism to mediate substrate polyubiquitination 28 . First, APC11 activates Ub transfer from an E2 (often UBCH10 in human cells) directly to the substrate [29] [30] [31] [32] . Second, another E2 (UBE2S in humans [32] [33] [34] [35] ) transfers Ub to a substrate-ligated Ub to mediate chain elongation 28, 36 .
Because of the large quantities of APC/C required to dissect mechanisms underlying EMI1-mediated inhibition, we turned to a recombinant APC/C system 37 . The hallmark features of endogenous human APC/C were recapitulated in our assays using a fluorescently tagged cyclin B Nterminal domain (cycB-NT*) as the substrate: ubiquitination depends on APC/C and CDH1, with low-molecular-weight products being formed by UBCH10, high-molecular-weight (HMW) products being formed by UBCH10 and UBE2S together, and inhibition being produced by EMI1-SKP1 and EMI1 DLZT (Fig. 3a) . This prompted us to develop assays to separately investigate APC/C-mediated ubiquitination with the two E2s. We were able to quantify APC/C CDH1 -UBCH10-mediated ubiquitination of both cycB-NT* and a fluorescent Ub fusion (UbcycB-NT*), which is also a substrate for APC/C CDH1 -UBE2S-mediated ubiquitination even in the absence of UBCH10 (Fig. 3b) .
We first performed a series of titrations to determine the saturating concentrations of CDH1 and identify conditions in which the ubiquitination reactions were in initial rate regimes ( Supplementary  Figs. 3-5 ). Subsequent titrations of UBCH10, UBE2S and substrate allowed measurement of K m values (Supplementary Fig. 3d ). The K m of 290 ± 80 nM for cycB-NT* in reactions with UBCH10 closely agrees npg a r t i c l e s with previous measurements of 228 and 63 nM for similar substrates with immunopurified endogenous Xenopus laevis and Saccharomyces cerevisiae APC/C, respectively 38, 39 . Experiments with EMI1-SKP1 revealed tight binding inhibition, which we quantified using the Morrison equation 40 . Performing experiments under initial rate conditions required our use of 5 nM APC/C CDH1 , for which the tight binding nature of EMI1 and data quality at the stoichiometric point (1:1 APC/C CDH1 :EMI1) restricted our accurate quantification of apparent K i (K i app ) values to a lower limit of 2.5 nM (Supplementary Fig. 5d ). Titration of EMI1-SKP1 revealed K i app values of ≤2.5 nM, and potentially substantially lower, for APC/C CDH1 -mediated substrate ubiquitination with both UBCH10 and UBE2S, as approximately 5 nM of EMI1-SKP1 completely inhibits these reactions ( Table 1) . Similar results were obtained for a version lacking the EMI1 N terminus or the entire N-terminal domain and F-box-SKP1, which consisted exclusively of the C-terminal D-box, linker, ZBR and tail regions. Below we describe how the distinct elements within EMI1 DLZT contribute to a tight binding mode of APC/C CDH1 inhibition.
EMI1 has an essential but relatively weak D-box
An obvious key functional element is EMI1's D-box. In examining the EM data, there were differences between APC/C CDH1 and the EMI1-SKP1-and EMI1 DLZT -bound complexes in the vicinity of CDH1 and APC10, consistent with EMI1's D-box binding the co-receptors (Supplementary Fig. 2 ). We were unable to generate stoichiometric complexes for mutants lacking EMI1's D-box.
Furthermore, alanine substitutions in place of Arg322 and Leu325 in EMI1 DLZT 's D-box RxxL motif decreased inhibition of cycB-NT* in reactions with UBCH10 to the point that we could not measure a K i under the initial rate conditions ( Table 1) . The K i app increased by over two orders of magnitude for UbcycB-NT* ubiquitination by APC/C CDH1 and UBE2S.
Despite its requirement, the EMI1 D-box on its own is relatively weak: an isolated EMI1 D peptide is insufficient as an inhibitor even at the 100 µM concentration we could achieve in our assays. This contrasts with an isolated D-box peptide from the S. cerevisiae APC/C substrate Hsl1 (ref. 41) , which is a more potent inhibitor (Fig. 3c,d ).
EMI1 elements synergize to inhibit substrate ubiquitination
In order to map the locations of the remaining portions of EMI1, we generated single-particle EM reconstructions for mutants in EMI1 FDLZT -SKP1 with insertions between residues 354 and 355 in the linker upstream of the ZBR and at the C terminus of EMI1 (Fig. 4a) . In this latter case, it was necessary to replace the EMI1 D-box with that from Hsl1 to enhance complex formation. The insertions contained the β-propeller from S. cerevisiae Doa1, which has N and C termini in close proximity 42 . Although we cannot be certain that the insertions do not alter native interactions, the data are consistent with the linker projecting away from the D-box bound to CDH1 and APC10 and toward the APC/C platform and catalytic core and with the ZBR and tail extending across the platform (Fig. 4a,b) .
Prompted by the structural data showing that an insertion maps to the central location between the D-box co-receptor APC10, the (Fig. 4a) , we considered that the linker might be functionally important. Indeed, the linker is not simply a spatial connector joining the D-box and ZBR effectors: deleting 20 linker residues impairs EMI1 DLZT -mediated inhibition, which is not restored by replacing them with a 20-residue, glycine-rich sequence (Fig. 4c,d) . As a first attempt to address whether this sequence or structure may be important, we tested two 10-residue deletions and found only one to cause severely impaired inhibition. Triply mutating conserved Leu345, Tyr356 and Arg358 within the essential sequence to alanines, either in the context of the benign 10-residue deletion or in EMI1 DLZT , was sufficient to substantially impair inhibition. Thus, specific side chains within the linker contribute to inhibition (Fig. 4d) . One reason the linker or other C-terminal elements may be important would be to compensate for EMI1's relatively weak D-box. Inhibitory roles of regions other than the D-box are reflected by the D-box-mutated version of EMI1 D(Mut)LZT inhibiting formation of HMW conjugates after extended reaction times with UBCH10 despite causing no measurable inhibition under initial rate conditions (Fig. 4d , Table 1 and Supplementary Fig. 6 ). In contrast, grafting the Hsl1 'Super'D-box into EMI1 DLZT largely overcame the defects resulting from deleting the linker, even in combination with the ZBR-unfolding C409A mutation (Fig. 4d) . Thus, it appears that EMI1's weak but essential D-box must function combinatorially with additional elements for optimal inhibition. C-terminal deletions, which retained the D-box and linker (EMI1 FDLZ and EMI1 FDL ) but lacked the tail or both the ZBR and tail, inhibited the reactions with both E2-substrate pairs, with K i app values increased by more than two orders of magnitude. Notably, deleting the ZBR had little effect in the absence of the EMI1 C-terminal tail; this underscores the importance of the tail in functioning with the D-box and/or linker to maximally inhibit APC/C CDH1 activity with both E2s (Table 1) . Taken together, the data suggest that the D-box, linker, ZBR and tail bind multiple sites on APC/C CDH1 to synergistically antagonize ubiquitination activity.
NMR structure and inhibitory surface of the EMI1 ZBR
To gain insights into potential contributions of the ZBR in APC/C inhibition, we assigned backbone and side-chain resonances of 13 C, 15 N-labeled EMI1 ZT and determined the solution structure (Fig. 5a,b and Table 2 ). Although the EMI1 ZT construct spans residues 363-447, only residues 375-420 exhibited the features of a folded domain, with a central, twisted, four-stranded β-sheet and two zinc ions on opposite ends of the sheet. One zinc is chelated by the β1-β2 and β3-β4 loops, and the other by the β2-β3 loop and a loop following β4. The ZBR displays an In-Between-RING (IBR) domain topology, aligning with the IBR of RNF31 with 5.5 Å r.m.s. deviation.
The NMR structure enabled identification of a functionally important surface on the ZBR through alanine-scanning mutagenesis of EMI1 DLZT . Under conditions in which APC/C CDH1 is insensitive to a version of EMI1 lacking the ZBR and tail (EMI1 NFDL ) but is inhibited by wild-type EMI1 DLZT , several mutants impaired EMI1 DLZT -mediated inhibition of APC/C CDH1 ubiquitination with either UBCH10 or UBE2S (not shown) (Fig. 5c,d) . The majority of defective mutants (L375A, K376A, R380A N382A, K386 D388A, Y387A, P384A) mapped to a single surface (Fig. 5e,f) . The diminished inhibition caused by the three most deleterious individual alanine mutants-at positions Leu375, Lys376 and Arg393-resembled that caused by unfolding the ZBR through mutation of the Cys409 zinc ligand (Fig. 5d) . Although we found the R393A mutant to also be unfolded, NMR analysis of 15 N-labeled samples confirmed folding of the L375A and K376A mutants (Supplementary Fig. 7) , suggesting that the ZBR is not solely a structured tether between the linker and tail. Rather, the surface harboring these residues is important for inhibition. Leu375 and Lys376 are at the N terminus of the ZBR domain, suggesting spatial proximity between the inhibitory ZBR surface and the upstream linker sequence in EMI1.
ZBR and C-terminal tail synergize to block chain elongation
A distinctive pattern of inhibition was observed for the EMI1 fragment consisting only of the ZBR and tail, which on its own inhibited APC/C CDH1 -UBE2S-mediated ubiquitination of UbcycB-NT*, although relatively weakly, with a K i app of 520 nM ( Table 1) . The ZBR and tail synergize, as we could not measure inhibition with the isolated ZBR at the highest concentration we could achieve, and the K i app increased to 42 µM for a synthetic peptide corresponding to the isolated EMI1 T . We did not observe obvious effects of EMI1 ZT on the initial rate of Ub ligation by UBCH10 ( Table 1) .
Because the EM data indicated that the EMI1 ZT region interacts with the APC/C catalytic core and/or platform regions (Fig. 4a) , we tested whether EMI1 ZT inhibits APC/C CDH1 -UBE2S-mediated Ub ligation independently of counteracting substrates recruited to the distal D-box binding site. Even though UBE2S binds coactivator proteins 34, 43 and generates Ub chains even in the absence of an E3 (ref. 44 ), we identified conditions in which APC/C stimulated UBE2S-mediated ubiquitination of UbcycB-NT* even in the absence of CDH1 (Fig. 3b  and Fig. 6a) . Although the K i for full-length EMI1 increased substantially, presumably due to lack of its D-box recruitment by CDH1, the isolated EMI1 T inhibited APC/C-UBE2S-mediated ubiquitination of UbcycB-NT* equally well in the presence or absence of CDH1 ( Table 1 and Fig. 6a,b) . 
npg a r t i c l e s
The indifference to CDH1 implied that the isolated EMI1 T targets a catalytic function of APC/C-UBE2S independently of blocking APC/C binding to a D-box substrate. We developed an assay for APC/Cand UBE2S-dependent synthesis of di-Ub chains, using as a substrate a Ub variant labeled with fluorescein on a C-terminal cysteine (Fig. 6c,d) . Full-length EMI1 remained a superior inhibitor, with an order-of-magnitude lower K i app than that measured for EMI1 ZT even for this substrate-independent Ub chain formation, suggesting that the structurally observed multisite APC/C binding enhances EMI1 inhibition of catalysis. Full-length EMI1 and EMI1 D(Mut)LZT displayed similar degrees of inhibition, consistent with the notion that the D-box is recruited to CDH1. Inhibitory effects of EMI1 ZT , EMI1 Z and EMI1 T roughly paralleled those observed in CDH1-dependent ubiquitination of UbcycB-NT* ( Table 1) . Thus, EMI1 T inhibits APC/C-UBE2S-catalyzed Ub-chain formation. Furthermore, this appears to be the case even in assays containing both UBE2S and UBCH10, as upon adding high concentrations of the shorter EMI1 ZT , we observed a selective decrease in the HMW products corresponding to those generated when UBE2S was included in the reactions (Fig. 6e) . Comparing EMI1 and UBE2S sequences provides a rationale for the E2 selectivity, as the conserved residues in their C-terminal sequences are identical (Fig. 6f) . Previous studies showed that the unique UBE2S C-terminal sequence is essential for APC/C recruitment 34, 35 .
DISCUSSION
At a global level, EMI1 shares some features with the other APC/C inhibitor, MCC. Both occupy the APC/C central cavity, on one end mimicking bound substrate and on the other binding and structurally reorganizing the platform to lock APC/C in a closed state (Supplementary Fig. 8 ) 5, 45, 46 . However, whereas the MCC is ~200 kDa and includes CDC20, APC/C is shut down by only a 143-residue C-terminal inhibitory domain from EMI1. Importantly, EMI1 is a distinct entity from CDH1, explaining how EMI1 can bind to APC/C already assembled with CDH1. Furthermore, between the EM data showing EMI1 contacting the APC/C catalytic core and biochemical data analyzing reactions inhibited by EMI1, we also uncovered a function for the unstructured C-terminal tail of EMI1 in blocking catalysis of Ub-chain elongation by UBE2S. As both EMI1 and UBE2S are found only in higher eukaryotes, this selective antagonism and the similar C-terminal sequences may reflect more recent evolution to bind a common site on APC/C from higher organisms. 
npg a r t i c l e s
Alternatively, a key EMI1 function may be to block Ub-chain elongation. UBE2S is apparently required for normal mitosis only in a subset of cell types but in other cells may be important for recovery from the spindle checkpoint 33, 34 . UBE2S-mediated Ub-chain elongation is thought to be particularly important for substrates with few lysines serving as sites of initial Ub ligation and may also be important for substrates whose turnover is regulated by deubiquitinating enzymes 32 . Thus, by extension, such substrates might also be especially sensitive to regulation by EMI1. Notably, we found that EMI1's APC/C inhibitory domain is substantially natively disordered, thus defining a distinct structural class of E3 inhibitor and differing not only from the crystallographically characterized MCC but also from several other RING E3 inhibitors 2, 3, 9 . Intrinsic disorder enables a small sequence to have multiple discrete interaction motifs that mediate binding to multiple sites 47 . Consistent with prior studies, we detected inhibition by isolated D-box and EMI1 C-terminal tail peptides 23, 48 . Our data also indicate that the linker and ZBR do not simply serve as spacers between the EMI1 D-box and C-terminal tail. We defined, for the first time, the linker as an effector of EMI1 function and identified surfaces on the linker and ZBR important for inhibiting APC/C. Each element is weak on its own, and the combination of the multiple motifs is required for maximal inhibition (Fig. 7) .
The structural data provide a rationale for many previously described features of EMI1 regulation. In addition to inhibition by the C-terminal domain 22, 23 , EMI1 also plays a role in localizing a fraction of APC/C to spindle poles 18 . EM structures reveal that EMI1's N-terminal domain, which binds NuMA-dynein-dynactin to mediate localization, is exposed on the surface and available for interaction without disrupting contacts anchoring the C-terminal domain to APC/C CDH1 (Supplementary Fig. 2d ). Ultimately, cell-cycle progression requires APC/C's liberation from EMI1. The exterior location of EMI1's N-terminal domain also explains how this region can be phosphorylated and ubiquitinated to signal EMI1 degradation before nuclear envelope breakdown 14, 20 . Human EMI1's C-terminal domain is also blocked from APC/C binding through mitotic cyclindependent kinase-mediated phosphorylation 49 . These sites map to the EMI1 D-box and to within 5 Å of a bound zinc and the ZBR surface we identified as required for inhibition (Fig. 5f) . It seems likely that EMI1's multisite binding to APC/C would enable the individual elements to fluctuate on and off, which would allow phosphorylation, in turn diminishing capacity for their rebinding and ultimately leading to separation from APC/C.
Although mechanisms by which intrinsic disorder can modulate protein function are only beginning to emerge, it is likely that many small, substantially intrinsically disordered domains utilize several elements to dynamically regulate multiple functionalities of massive molecular machines many times their size. As 30% of the human proteome is estimated to be natively unstructured 25 , we anticipate that future studies will reveal other forms of E3-ligase regulation that depend on specialized features established by protein disorder.
METHODS
Methods and any associated references are available in the online version of the paper.
